Grant: CIHR Fellowship
Direct Payment
$120,833.00
Role of microRNAs in pancreatic cancer metastasis
FY 2012-13
Summary
Cancer is one of the leading causes of death in North America. Almost 90% of cancer-related deaths are due to metastasis, a process whereby cancer cells spread from the primary to distant sites within the body. The latter highlights the necessity to elucidate the mechanisms and players involved in the metastatic process.
MicroRNAs are small molecules that are found inside cells. They have the ability to control the way cells function, and thereby interact with other cells. Recent studies have also implicated microRNAs with tumour progression. Intriguingly, a recent groundbreaking study by the laboratory of Dr. Douglas Hanahan has identified a number of microRNAs that are associated with pancreatic cancer metastasis in mouse models. Preliminary data suggest that several may act alone or together to promote pancreatic cancer metastasis to the liver.
The goal of the current project is to further characterize and identify which microRNAs have the ability to enhance the capability of pancreatic tumour cells to metastasize to other tissues. For this purpose, we will first use mouse models of pancreatic cancer. Once we identify the microRNAs that have the capacity to increase the metastatic ability of pancreatic tumours, we will then examine whether these microRNAs are potentially associated with pancreatic cancer metastasis in human patients. We will finally attempt to understand how they influence tumour spread, for example whether they affect the way tumour cells interact with neighboring cells or invade the surrounding tissue.
This study will further the understanding of the metastatic process, and may aid in the design of therapeutic strategies aiming to inhibit metastasis, and therefore improve survival of cancer patients.
Department
Program
CIHR Fellowship
Recipient
Location
Switzerland
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
281389
Name
Michael Iacovos P
Country
Switzerland
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Role of microRNAs in pancreatic cancer metastasis
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$120,833
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Metastasis; Micrornas; Pancreatic Cancer
Abstract
Cancer is one of the leading causes of death in North America. Almost 90% of cancer-related deaths are due to metastasis, a process whereby cancer cells spread from the primary to distant sites within the body. The latter highlights the necessity to elucidate the mechanisms and players involved in the metastatic process.
MicroRNAs are small molecules that are found inside cells. They have the ability to control the way cells function, and thereby interact with other cells. Recent studies have also implicated microRNAs with tumour progression. Intriguingly, a recent groundbreaking study by the laboratory of Dr. Douglas Hanahan has identified a number of microRNAs that are associated with pancreatic cancer metastasis in mouse models. Preliminary data suggest that several may act alone or together to promote pancreatic cancer metastasis to the liver.
The goal of the current project is to further characterize and identify which microRNAs have the ability to enhance the capability of pancreatic tumour cells to metastasize to other tissues. For this purpose, we will first use mouse models of pancreatic cancer. Once we identify the microRNAs that have the capacity to increase the metastatic ability of pancreatic tumours, we will then examine whether these microRNAs are potentially associated with pancreatic cancer metastasis in human patients. We will finally attempt to understand how they influence tumour spread, for example whether they affect the way tumour cells interact with neighboring cells or invade the surrounding tissue.
This study will further the understanding of the metastatic process, and may aid in the design of therapeutic strategies aiming to inhibit metastasis, and therefore improve survival of cancer patients.
Competitiondate
201302
Approvedterm2
2 yrs 5 mths
Pinamesdelim
Michael, Iacovos P
Approvedterm
2 ans 5 mois
Cihrcontribution2
~ $120,833~ $0~